Skip to content
#diffusion models Open access

Neuroinflammation in Neurodegenerative Diseases: A Narrative Update (2020–2026) on Metabolic, Molecular, Morphological, and Functional Imaging

Sep 2026 · Discover medicine · 0 citations

TL;DR

Current evidence supports neuroinflammation imaging primarily for mechanistic investigation, patient stratification, and trial enrichment rather than routine clinical deployment, and should therefore be interpreted as a collection of target-specific, stage-dependent biological readouts rather than as a unitary measure of inflammation.

Abstract

Neuroinflammation is increasingly recognized as a biologically relevant component of neurodegenerative disease, yet its in vivo imaging remains difficult to interpret. This narrative update synthesizes original imaging studies published between January 1, 2020, and May 17, 2026, and examines how positron emission tomography (PET), magnetic resonance imaging (MRI), and hybrid or multimodal approaches characterize glial and neurovascular processes. The most extensive human evidence is available for Alzheimer’s disease, in which translocator protein (TSPO) PET has been associated with tau burden, amyloid-β deposition, Braak-like propagation, cognitive decline, network dysfunction, and genotype-dependent disease biology. In frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, Parkinson’s disease, and multiple system atrophy, evidence is more limited and heterogeneous; nevertheless, selected studies support mechanistic phenotyping, prognostic enrichment, and, in multiple system atrophy, formal differential-diagnostic testing. Emerging targets include monoamine oxidase-B, colony-stimulating factor 1 receptor, P2X7 receptor, and acetate metabolism, whereas fluorodeoxyglucose (FDG) PET, diffusion MRI, quantitative susceptibility mapping, and blood-brain barrier imaging provide complementary metabolic, microstructural, and neurovascular information. Neuroinflammation imaging should therefore be interpreted as a collection of target-specific, stage-dependent biological readouts rather than as a unitary measure of inflammation. Because most studies report associations, colocalization, or prognostic models rather than diagnostic accuracy, sensitivity and specificity are discussed only when explicitly evaluated in the original study. Current evidence supports neuroinflammation imaging primarily for mechanistic investigation, patient stratification, and trial enrichment rather than routine clinical deployment.

Read PDF

Similar papers

Review Open access Aug 2026

Microglia-mediated neuroinflammation in Alzheimer’s disease: mechanisms and emerging therapeutic targets

A “cellular state–pathological network–therapeutic window” framework is proposed and the roles of microglia in amyloid-β plaque seeding and compaction, NLRP3 inflammasome activation, mitochondrial DNA–cGAS–STING signaling, complement-mediated synaptic engulfment, and bidirectional microglia–tau feedback are systematica...

Lian-Jing Xu, Ying Zhang, Li Jiang et al. · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

This narrative review examines AD mechanisms, biomarkers, and therapeutic prospects from a geroscience perspective and applies the eight hallmarks of neurodegenerative diseases as an analytical framework to establish which preventive strategies and biomarker-guided, stage-matched combination therapies improve clinicall...

P. Chmielewski · 0 citations
Review Open access Jul 2026

Alzheimer's disease heterogeneity and co‐pathologies: Defining novel targets, biomarkers, modalities, and research methodologies

Key takeaways from the Fall 2025 AARR meeting are presented, which brought together academic, clinical, and industry leaders to discuss and explore the current advances in the heterogeneity and co‐pathologies of AD and their implications for diagnosis, clinical trial design, and precision treatment strategies.

M. Tansey, S. Bozeat, Peter Ackerman et al. · 0 citations
Review Open access Oct 2026

Noninvasive diagnosis of Alzheimer’s disease: a review of emerging biomarkers and multimodal approaches

Noninvasive biomarkers are expanding access to biological assessment of Alzheimer’s disease (AD). This review evaluates blood-based, neuroimaging, retinal, electrophysiological, digital, and behavioral measures alongside structured cognitive and functional assessment, and examines multimodal and machine-learning approa...

Jun-Sheng Zhao, Cheng-Qi Nie, Rong Gao et al. · 0 citations
Review Open access 2026

Immunotherapeutic Strategies Targeting Amyloid-β and Tau in Alzheimer’s Disease: A Systematic Review of Clinical Efficacy, Safety, and Translational Limitations

Alzheimer’s disease (AD) is one of the leading neurodegenerative disorders affecting over 55 million individuals worldwide, with a limited selection of disease-modifying therapies. The amyloid cascade hypothesis proposes that amyloid-beta (Aβ) peptide accumulation initiates a cascade of synaptic dysfunction, neuroinfla...

R. Menon · 0 citations
Review Open access Sep 2026

The Role of Neuroinflammation in Alzheimer's Disease: Molecular Mechanisms and Emerging Therapeutic Approaches

This review examines the molecular and cellular mechanisms through which neuroinflammation contributes to the progression of AD, with particular emphasis on microglial activation, TREM2 and soluble TREM2 (sTREM2) signaling, NLRP3 inflammasome activation, astrocyte–microglia interactions, and blood–brain barrier dysfunc...

Shreyansh Goswami · 0 citations

Related blog posts

Microsoft Research Blog Nov 16, 2026

TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient

AI coding agents are increasingly help developers fix bugs and build features largely on their own, but every interaction with their models consumes tokens. In each session, an agent sends instructions, tool descriptions, and session history to its model. Most efforts to reduce this cost focus on individual tasks. Yet developers return to the same […] The post TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.